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Abstract: Heart failure represents a major source of morbidity and mortality in industrialized nations. As the leading hos-
pital discharge diagnosis in the United States in patients over the age of 65, it is also associated with substantial economic 
costs. While the acute symptoms of volume overload frequently precipitate inpatient admission, it is the symptoms of 
chronic heart failure, including fatigue, exercise intolerance and exertional dyspnea, that impact quality of life. Over the 
last two decades, research into the enzymatic, histologic and neurohumoral alterations seen with heart failure have re-
vealed that hemodynamic derangements do not necessarily correlate with symptoms. This “hemodynamic paradox” is ex-
plained by alterations in the skeletal musculature that occur in response to hemodynamic derangements. Importantly, gen-
der specific effects appear to modify both disease pathophysiology and response to therapy. The following review will 
discuss our current understanding of the systemic effects of heart failure before examining how exercise training and car-
diac resynchronization therapy may impact disease course.  
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INTRODUCTION 
  As the leading hospital discharge diagnosis for patients 
over the age of 65, chronic heart failure (CHF) represents a 
major source of morbidity and mortality in the United 
States[1]. Continued advances in the treatment of acute 
coronary syndromes promise only to increase the number 
beyond the over 550,000 new diagnoses made annually [2]. 
Despite advances in both pharmacologic and device thera-
pies that have dramatically altered the natural history of 
CHF, disability associated with the symptom complex re-
mains a major source of morbidity [2]. This symptom com-
plex can be loosely divided into the acute symptoms of vol-
ume overload and the chronic symptoms of exercise intoler-
ance, fatigue and exertional dyspnea. These chronic symp-
toms, in particular, dramatically impact quality of life. 
  Over the last two decades, several different lines of evi-
dence have converged to identify skeletal muscle pathology 
as a major contributor to exercise intolerance and its atten-
dant disability in chronic heart failure [3]. While numerous 
studies have linked enzymatic and histologic abnormalities 
with exercise intolerance, the underlying mechanisms driv-
ing these processes remain poorly understood [4-6]. Impor-
tantly, hemodynamic improvements do not acutely reverse 
this process. This “hemodynamic paradox” has spawned an 
enormous body of literature that collectively implicates dys-
function of oxygen utilization by skeletal musculature as 
being central to the symptom complex [7,8]. The following 
review will examine the role of the peripheral musculature in 
contributing to the morbidity associated with CHF before 
offering insight into how two seemingly disparate therapies – 
exercise training and cardiac resynchronization therapy – 
might improve exercise intolerance. In addition, we will   
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explore how the various contributing factors are influenced 
by gender.  
HEMODYNAMICS 
  The reduced exercise tolerance observed in CHF has long 
been viewed as a direct consequence of decreased cardiac 
function. In support of this paradigm, exercise capacity as 
measured by peak oxygen consumption (VO2) is strongly 
correlated with cardiac output (CO). This correlation is sup-
ported by numerous studies over the past 15 years [9-11]. 
Resting indices of ventricular function (i.e., left ventricular 
ejection fraction, left ventricular end diastolic dimension, 
mean velocity of circumferential fiber shortening, and ratio 
of pre-ejection period to LV ejection time), however, are 
unrelated to exercise capacity or symptom status in CHF 
[9,12,13]. There are at least three reasons why resting indices 
of ventricular function do not relate to exercise capacity. 
First, resting parameters are unable to account for cardiac 
functional reserve. Second, resting indices do not address the 
role that both sympathetic drive and peripheral hemodynam-
ics (i.e., the ability of the capillary bed to dilate or constrict 
in response to exercise) have on exercise capacity. Finally, 
resting indices of ventricular function fail to account for in-
trinsic alterations in the skeletal musculature that been found 
to at least partly account for the observed exercise intoler-
ance in patients with CHF [5,14-16]. 
  The importance of these last two points becomes appar-
ent when one considers the determinants of peak oxygen 
consumption as described by the Fick equation, VO2=CO* 
AVO2, where VO2 represents oxygen consumption, CO 
represents cardiac output, and AVO2 represents arterio-
venous oxygen difference. As a decrease in cardiac output is 
the sine qua non of chronic heart failure, augmentation of 
cardiac output would be expected to increase exercise capac-
ity and peak oxygen consumption. However, in CHF, phar-
macologic based improvements in cardiac output do not 
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either peak VO2 or symptoms [7, 8, 17]. In fact, it is as if the 
peripheral skeletal muscle abnormalities serve as a block in 
the translation of changes in cardiac output into improve-
ments in exercise capacity and symptoms. Several different 
studies using vasodilators and inotropic agents have illus-
trated this point. In a study of ten patients with chronic heart 
failure hydralazine was shown to increase maximal exercise 
cardiac output (5.6 ± 0.7 to 6.7 ± 0.6 l/min; p<0.01) but had 
no effect on peak VO2 (787 ± 105 versus 779 ± 82 ml/min) 
[8]. Similarly, Maskin and colleagues evaluated the acute 
hemodynamic and metabolic effects of dobutamine in eight 
patients with NYHA III - IV chronic heart failure. While 
administration of dobutamine increased cardiac index during 
peak exercise from 2.67 ± 0.59 liters/min/m
2 to 3.23 ± 0.78 
liters/min/m
2 (p<0.001), it did not increase exercise capacity 
(4.8 ± 1.5 min versus 4.5 ± 1.2 min) [7].  
 As  VO2 is linearly related to cardiac output, the lack of 
improvement in VO2 with augmentation of cardiac output 
implies a corresponding reduction in AVO2. Experimental 
models support this interpretation. If cardiac output is in-
creased at rest and during exercise with dobutamine, there is 
almost no increase in oxygen consumption due to a propor-
tionate decrease in AVO2, as demonstrated in the afore-
mentioned study of the hemodynamic affects of dobutamine 
on exercise capacity in severe CHF [7]. This “hemodynamic 
paradox” suggests that, in patients with CHF, alterations in 
peripheral oxygen consumption play a critical role in exer-
cise capacity and fatigue. While these alterations do not di-
rectly affect the relationship between peak VO2 and cardiac 
output, they serve to inhibit the translation of acute changes 
in peak cardiac output to changes in peak VO2.
MORPHOLOGIC, HISTOLOGIC AND ENZYMATIC 
CHANGES OF SKELETAL MUSCLE IN CHRONIC 
HEART FAILURE 
  Cardiac cachexia, defined as greater than a 6.0% weight 
loss over a six month period in the absence of other cachetic 
states (i.e., cancer), affects 10 - 16% of patients with chronic 
heart failure [18-20]. While cardiac cachexia represents the 
most extreme form of loss of muscle mass in chronic heart 
failure, a more subtle form of lean body mass changes 
clearly exists, as evident by the loss of skeletal muscle ob-
served in patients with non-cachetic congestive heart failure 
(Fig. 1) [21, 22]. Conceptually, the skeletal muscle altera-
tions seen with CHF can be divided into histologic changes 
and biochemical changes.  
  Multiple different morphologic and histologic abnormali-
ties have been described in patients with severe chronic heart 
failure. These include muscle fiber atrophy, altered capillary 
density, reduced maximal strength, and decreased electro-
myographic activity [21, 23-24]. Work by Sullivan and col-
leagues identified several additional histologic and morphol-
ogic changes that occur with chronic heart failure. Using 
vastus lateralis skeletal muscle biopsies from eleven patients 
with chronic heart failure and nine control subjects, Sullivan 
et al. demonstrated that patients with chronic heart failure 
have a reduced percentage of slow twitch type I fibers (36 ± 
7% versus 52 ± 22%, p<0.05) and a higher percentage of 
type IIb fast twitch fibers (24 ± 9% vs. 11 ± 12%, p<0.05) 
[6]. Corollary studies exploring skeletal muscle myosin iso-
form expression in patients with CHF have demonstrated a 
reduction in myosin heavy chain type I. These results mirror 
the aforementioned histologic observations, as myosin heavy 
chain expression differs according to fiber type and is more 
abundant in type I aerobic fibers [16].  
   In addition to having an increased proportion of glyco-
lytic fibers, patients with CHF also have clear alterations in 
their ability to supply oxygen to the muscle fibers via the 
capillary bed. Within a given individual, oxidative (red) 
skeletal muscles have a two- to four-times greater vascular 
density than glycolytic (white) muscles; cardiac muscle may 
be as much as ten times greater [25]. More important, this is 
a dynamic process, as evident by the increase in vascular 
density seen with exercise conditioning [26]. While capillary 
density has been variably identified as a histologic abnormal-
ity associated with chronic heart failure and exercise intoler-
ance [27], recent studies that control for gender and exercise 
capacity (peak VO2) have demonstrated intriguing results. 
Duscha et al. compared 22 men with CHF to 10 sedentary 
controls matched for exercise capacity and found that capil-
lary density as determined by endothelial cells per muscle 
fiber was decreased in men with CHF, implying that the ab-
normality was an intrinsic part of the disease state and not a 
consequence of deconditioning itself. Moreover, capillary 
density amongst men with CHF was inversely related to 
oxygen consumption (r = 0.479, p = 0.02) [15]. In their study 
of 38 patients with chronic heart failure (25 men, 13 
women), Duscha and colleagues demonstrated that whereas 
men with CHF have an inverse relationship between capil-
lary density and exercise capacity, no such relationship exists 
among women [28]. However, it should be noted that women 
with CHF had higher capillary density than their normal fe-
male counterparts, the opposite of the finding for men.  
  Tyni-Lenne and colleagues have provided additional in-
sight into the morphologic differences between men and 
women with heart failure. In contrast to men with heart fail-
ure, who have a decreased proportion of type I slow twitch 
fibers, women with heart failure have a normal proportion of 
type I fibers but decreased cross sectional area of both type I 
and type II fibers [29]. Two conclusions can be drawn from 
these studies: (1) the inverse relationship between capillary 
density and peak VO2 implicates an adaptive response in 
men to the disease state; (2) the myopathy associated with 
Fig. (1). Relationship between exercise capacity and lean muscle 
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CHF is influenced by gender. Clearly, additional research is 
needed into how angiogenic factors control capillary density 
and how this is influenced by gender-specific effects.    
  In addition to the histologic and morphologic changes 
seen in the musculature of patients with CHF, several studies 
have examined CHF-associated changes in the rate limiting 
steps of glycolytic and oxidative pathways [4,6]. Sullivan 
and colleagues explored this question by performing enzy-
matic analysis of muscle biopsies from 11 patients with CHF 
and comparing them to those of 9 control patients. Bio-
chemical analysis demonstrated decreased activity of en-
zymes involved in oxidative pathways, such as succinate 
dehydrogenase (51 ± 15 versus 81 ±18 microM/g pro-
tein/min, p<0.001) and citrate synthetase (26 ± 7 versus 43 ± 
20 microM/g protein/min, p < 0.05), but no change in the 
activity of enzymes involved in glycolytic pathways [4]. 
Sullivan’s work confirmed the results of Mancini and col-
leagues, who demonstrated a reduction in enzymes of aero-
bic metabolism such as beta-hydroxyacyl CoA dehydro-
genase activity [23]. These enzymatic changes are mirrored 
histologically by a decrease in mitochondrial volume and 
functionally by a reduction in peak VO2. In their study of 57 
patients with severe CHF, Drexler and colleagues found that 
both mitochondrial surface area and density decreased by 
approximately 20% when compared to controls. Interest-
ingly, the reduction in mitochondrial volume was independ-
ent of patient age or etiology of heart failure [24]. 
  Collectively, the morphologic, histologic and enzymatic 
changes seen in chronic heart failure are the manifestations 
of a systemic process where peak VO2 is limited not by 
hemodynamics, but by the oxidative capacity of the periph-
eral musculature. This observation has several implications. 
First, it raises the prospect that the myopathy of CHF is not 
being driven by hemodynamic derangements, but by altera-
tions in the milieu of neurohormonal factors, metabolites and 
cytokines that bathe the skeletal muscle. Second, in order to 
reverse or prevent cardiac cachexia, these factors need to be 
removed or decreased. Finally, as the profound morphologic, 
histologic and enzymatic changes seen with CHF are reflec-
tive of changes in gene expression that have occurred over 
months to years, interventions designed to reverse the proc-
ess must have an appropriate length of follow-up. Before 
discussing interventions, however, a discussion of the poten-
tial etiologic agents is warranted. While identified factors are 
certain to interact with one another, for simplicity they can 
be roughly divided up into immunologic and neurohormonal 
abnormalities. Fig. 2 provides a conceptual framework de-
picting how these factors might be interrelated.  
Fig. (2). Proposed model of how a reduction in cardiac output leads to a series of downstream effects that ultimately limit aerobic metabo-
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IMMUNOLOGIC ALTERATIONS IN CHRONIC 
HEART FAILURE 
  Cytokines are known to play a direct role in promoting 
skeletal muscle wasting. Tumor necrosis factor- (TNF-), 
IL-6, and IL-1 have all been observed to be elevated in both 
humans and animal models of chronic heart failure (see Ta-
ble  1). TNF-, in particular, appears to be central to this 
process, as it can directly induce skeletal muscle loss and is 
produced by the myocardium in response to increased ven-
tricular wall stress [32-35]. Not only are serum levels ele-
vated, but the magnitude of TNF- elevation correlates with 
disease severity [36-37]. Despite its apparent central role in 
contributing to cardiac cachexia, therapeutic trials with anti-
TNF therapy such as etanercept and infliximab have failed to 
show clinical benefit [36,38]. In fact, in the ATTACH trial, 
which randomized patients with NYHA Class III-IV chronic 
heart failure to placebo or infliximab, higher doses of TNF-
inhibition were associated with a three times increase in 
death or hospitalization at 28 weeks (hazard ratio 2.84, 95% 
CI 1.01-7.97, p=0.043) when compared with placebo [36]. 
Whether TNF- inhibition reversed skeletal muscle myopa-
thy was not evaluated and warrants further investigation.  
  The mechanism by which cytokines lead to muscle wast-
ing may be related to inducible nitric oxide synthase (iNOS) 
induction [39]. Hambrecht and colleagues demonstrated that 
heart failure patients have increased expression of iNOS. In 
this same study, they demonstrated that this was inversely 
correlated with exercise capacity, mitochondrial oxidative 
capacity and mitochondrial structural integrity [40]. More 
recently, Adams and colleagues observed that increased 
iNOS levels correlated with increased skeletal muscle apop-
tosis [41].
EFFECTS OF CHRONIC SYMPATHETIC ACTIVA-
TION IN CHRONIC HEART FAILURE 
  The deleterious effects of chronic sympathetic activation 
in heart failure has been recognized for close to two decades, 
and its antagonism has resulted in a major advance in treat-
ment, as evident by the clinical benefits of chronic beta 
blockade [42]. The role of chronic sympathetic stimulation in 
CHF associated skeletal muscle myopathy, however, has 
only recently begun to be appreciated. Chronic sympathetic 
activation appears to have at least three discernible effects on 
the skeletal musculature by: (1) impairing skeletal muscle 
blood flow; (2) up-regulating inflammatory cytokines; and 
(3) altering energy metabolism [31].  
  First, chronic sympathetic stimulation in patients with 
CHF promotes redistribution of blood flow to skeletal mus-
cles through chronic vasoconstriction [43-46]. Chronic under 
perfusion of the capillary bed, in turn, promotes skeletal 
muscle ischemia, which leads to the generation of reactive 
oxygen species and muscle inflammation [18,48,49]. Sec-
ond, a growing body of evidence suggests that sympathetic 
stimulation may be involved in the up-regulation of inflam-
matory cytokines. In patients with chronic heart failure, both 
TNF- and Il-6 have been noted to increase in parallel with 
plasma catecholamines [50]. This association holds true in 
patients without heart failure, as sympathetic activation in 
humans competing in marathons has been associated with a 
60 fold increase in cytokines, including IL-6 [31,51]. How 
sympathetic stimulation may lead to an increase in inflam-
matory cytokines is unclear, but may be related to the gen-
eration of reactive oxygen species and activation of NF-
[52]. Finally, chronic sympathetic stimulation via the beta 
adrenergic system alters the balance between glycogenolysis 
and gluconeogenesis, promoting a catabolic state. The resul-
tant increase in glycogen phosphorylase activity has been 
implicated in the increased venous lactate levels seen in re-
sponse to adrenergic stimulation [31, 53]. 
THERAPEUTIC OPTIONS IN THE TREATMENT OF 
CHF ASSOCIATED MYOPATHY 
  As evident by the discussion above, the role of the pe-
ripheral musculature in the symptom complex associated 
with CHF is only beginning to be elucidated. While no ther-
apy exists that directly reverses the myopathy, several differ-
Table 1.  Factors Involved in the Pathogenesis of Chronic Heart Failure Associated Skeletal Myopathy [30] 
Factor Effect Effect of Exercise Training
TNF- • Increased skeletal muscle apoptosis (Libera LD, J Mol 
Cell Cardiol 2001)
 skeletal muscle expression*
IL-6 • Inversely correlated with muscle fiber diameter (Larsen 
AI, et a. Inter J Cardiology)
 skeletal muscle expression*
IL-1-beta • Inversely correlated with muscle fiber cross sectional area 
and IGF expression (Schulz pc et a.).
 skeletal muscle expression*
iNOS • Increased skeletal muscle apoptosis  skeletal muscle expression*
Sympathetic Stimu-
lation 
31
• Arteriolar Constriction and Decreased Capillary Blood 
Flow 
• Increased Reactive Oxygen Species 
• Apoptosis 
• Inflammation and cytokine release 
• Augmented glycogenolysis
 tonic sympathetic tone and sympathetic stimulation of 
muscle96 Current Cardiology Reviews, 2008, Vol. 4, No. 2 Nilsson et al. 
ent treatment strategies currently employed in the treatment 
of CHF have the benefit of improving exercise capacity, in-
cluding exercise training and cardiac resynchronization ther-
apy (CRT). Further research into the effects of these thera-
pies on the skeletal muscle will hopefully further clarify the 
pathophysiology of CHF and lead to new treatment options.  
EXERCISE TRAINING IN CHRONIC HEART FAIL-
URE 
  Several small studies have demonstrated a benefit of ex-
ercise training in terms of both peak oxygen consumption 
and other measures of exercise capacity [5,54-57]. The ef-
fects of exercise training on the skeletal musculature, how-
ever, have not been as well defined. While several studies 
have suggested that exercise training reverses CHF associ-
ated myopathy as evident by increases in fiber size, percent-
age of aerobic fibers, oxidative metabolism, capillarity and 
mitochondrial size, these results have not been reproduced in 
all studies (Table 2) [15,30,58-65]. The discrepancy centers 
on whether exercise training reverses skeletal muscle myopa-
thy or simply enhances glycolytic, but not oxidative, capac-
ity.  
  Kiilavouri and colleagues randomized 27 patients with 
CHF to an aerobic training program (n=12) or control 
Table 2.  Effects of Exercise Training on Skeletal Muscle Histology, Enzymology and Immunology in Patients with Heart Failure 
Study Patient  Population  Training  Period  Findings 
Hambrecht R, et al.
(1995) [5]
 22 males 
 EF <40% 
 NYHA II-III 
6 months   19%  in mitochondrial volume density 
 41%  cytochrome c oxidase positive mitochondrial volume 
density.  
Belardinelli R et al.
(1995) [58]
 23 men, 4 women 
 EF 30% + 5% 
 NYHA II-III 
8 weeks   24%  in Type I and 17%  in Type II cross sectional area 
 5%  in capillary density 
 22%  in mitochondrial volume density 
Hambrecht R, et al.
(1997) [59]
 18 patients 
 26% + 10% 
6 months   41%  surface density of mitochondrial cytochrome c 
 43%  mitochondria cristae 
 “Reshift” from Type II to Type I fiber type  
Tyni-Lenne R, et al.
(1997) [60]
 16 women 
 EF ~ 30% 
 NYHA II-III 
8 weeks training, 8 
weeks non-training 
 32%  in oxidative capacity 
Tyni-Lenne R, et al.
(1999) [29] 
 24 men and women 
 EF 30% + 11% 
8 weeks of training   23%  in oxidative capacity in patients undergoing cycle train-
ing 
 45%  in oxidative capacity in patients undergoing aerobic 
knee extensor training 
Tyni-Lenne R, et al.
(1999) [61] 
 16 women 
 EF 28% + 8 
8 weeks   Decreased number of Type I fibers 
 Increased cross sectional area of muscle fibers 
Kiilavuori K, et al.
(2000) [62] 
 27 patients 
 NYHA II-III 
3 months   No change in capillary density 
 No change in fiber type 
 Increased anaerobic glycolysis 
 No change in oxidative capacity 
Larsen AI et al.
(2002) [63] 
 15 men and women 
 NYHA II-III 
 EF 33% + 5% 
12 weeks   Non-statistically significant increase in IIb fiber type thickness
 Non-statistically significant decrease in Type I fiber type 
thickness 
Santoro C, et al.
(2002) [64] 
 6 patients  16 weeks   23.4%  in mitochondrial size 
Keteyian SJ, et al.
(2003) [65] 
 10 men, 5 women 
 NYHA II-III 
EF <35% 
14-24 weeks   Increase in MHC class I in men but not women (38% v. -3%) 
 No change in capillary density 
 No change in enzymatic activity 
Gielen S, et al.
(2003) [30] 
 20 patients 
 EF 25% + 2% 
6 months   No change in serum TNF-, IL-1, IL-6 
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(n=15). The training group was subjected to a three month 
training program in which they exercised for 30 minutes, 
three times per week on a bicycle ergometer using a load that 
corresponded to 50 - 60% of their peak oxygen consumption. 
This was followed by a three month home training program. 
At the conclusion of the study, vastus lateralis biopsies were 
performed. While exercise capacity increased in the training 
group, enzymatic analysis of the muscle biopsies revealed an 
increase in activity of enzymes in the anaerobic glycolytic 
pathway. No increase activity was observed in the rate limit-
ing enzymes in the citric acid cycle or in fatty acid oxidation 
[62]. This was reflected histologically, as training had no 
effect on the proportion of slow twitch or fast twitch fibers, 
nor did it significantly alter capillary density.  
  Additional studies have demonstrated that while exercise 
does not alter the proportion of slow twitch to fast twitch 
fibers, there is a trend towards an exercise associated de-
crease in the cross sectional area of type I slow twitch fibers 
(p=0.062) and an increase in the cross sectional area of type 
IIb glycolytic fibers (p=0.068) [63]. In contrast with these 
studies, a recent study by Keteyian and colleagues demon-
strated an increase in the expression of the MHC I isoform, 
predominant in type I slow twitch fibers, in men with CHF 
who underwent exercise training [65]. Such changes were 
not observed in women, underscoring the importance of con-
ducting further research into how gender influences both 
disease pathophysiology and treatment strategies [65]. It also 
points out the limitations of generalizing the results of small 
studies, and mandates additional large research trials that are 
adequately powered to discern differences amongst sub-
groups.  
  In addition to affecting the morphologic, histologic and 
biochemical properties of skeletal muscle, exercise training 
has been shown to have an anti-inflammatory effect at the 
level of the skeletal muscle. In a trial of twenty men with 
stable chronic heart failure (EF 25% ± 2%) randomized to 
exercise training (n=10) or control (n=10), exercise training 
was shown to have no effect on systemic TNF-, IL-1-beta, 
or IL-6 levels but to have a profound effect on local expres-
sion in skeletal muscle. In addition, exercise training reduced 
local iNOS expression by 52% (6.3 ± 1.2 to 3.0 ± 1.0 U, 
p=0.007) [30]. How exercise training alters the local expres-
sion of inflammatory cytokines is unclear, but may be related 
to the approximately 50% reduction in levels of serum 
catecholamines that accompanies exercise training in heart 
failure patients [5]. Finally, it is possible the exercise training 
might benefit individuals with heart failure by removing the 
aforementioned block between the conversion of changes in 
cardiac output through medical therapy to changes in exer-
cise tolerance and peak performance. 
  While exercise training appears to improve the surrogate 
endpoints associated with CHF myopathy, the small sample 
size of published studies has precluded a determination of 
whether exercise training improves hard end points (i.e., 
mortality). The HF-ACTION trial is an ongoing randomized 
controlled trial studying the effects of exercise conditioning 
in over 2000 subjects with left ventricular ejection fractions 
of < 35% and NYHA class II-IV heart failure. Primary out-
comes include mortality and hospitalization for CHF. Impor-
tantly, individuals enrolled in HF-ACTION must be on a 
stable and optimal medical regimen for CHF that includes 
both an angiotensin converting enzyme inhibitor and a beta-
adrenergic blocking agent. Hopefully, the results of HF-
Fig. (3). Potential Influence of Exercise Training in Patients with Chronic Heart Failure 
Fig. (3) represents a conceptual framework that depicts the interrelationship between hemodynamics, peripheral perfusion and skeletal mus-
cle pathology in mediating the translation in cardiac output to impairment in function (peak VO2). In addition, the model depicts the potential 
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ACTION will address whether exercise training alters the 
natural history of CHF. Regardless of the outcome, HF-
ACTION will provide insight into the mechanisms of exer-
cise tolerance and will provide the backdrop for additional 
research projects.  
CARDIAC RESYNCHRONIZATION THERAPY AND 
EXERCISE CAPACITY 
  The advent of cardiac resynchronization therapy (CRT) 
for the treatment of patients with dyssynchrony and symp-
tomatic CHF despite optimal medical therapy ushered in a 
new era in the management of CHF, one in which devices 
that optimize the performance of the heart complement 
pharmacologic based therapies. To date, several thousand 
patients have been included in CRT trials and collectively 
they have conclusively demonstrated that CRT is associated 
with improvements in both exercise tolerance and peak oxy-
gen consumption [66]. Importantly, the follow-up in these 
trials was on the order of months, theoretically providing 
adequate time for the hemodynamic benefits of CRT to 
translate into alterations in the skeletal musculature (Fig. 2). 
At the level of the heart, CRT leads to improvements in sys-
tolic (e.g., EF) and diastolic function, a decrease in mitral 
regurgitation, a reduction in LV size and a reduction in myo-
cardial energy expenditure [67]. While the mechanisms by 
which CRT improves the symptoms of CHF has not been 
fully elucidated, the benefits appear to arise, at least in part, 
both directly from neurohumoral alterations and indirectly 
from exercise training.  
Fig. (4). Proposed model by which Cardiac Resynchronization 
Therapy (CRT) may lead to a feedback mechanism that leads to 
improved peripheral oxygen utilization.
  Several different studies looking at the effects of CRT on 
sympathetic stimulation have demonstrated, in aggregate, 
that CRT has a sympathoinhibitory effect [31]. While plasma 
catecholamine levels have yielded variable results in re-
sponse to CRT, muscle sympathetic nerve activity studies 
have consistently demonstrated both acute and chronic re-
duction in sympathetic activity [31]. This is illustrated by 
Grassi and colleagues who conducted a study of 11 patients 
with EF<35%, QRS >130 msec and NYHA III-IV symptoms 
who underwent CRT. After ten weeks of CRT, microneuro-
graphy demonstrated an approximate 30% reduction in sym-
pathetic activity [68]. Theoretically, reduction in sympathetic 
activity would then set up a feedback mechanism that would 
reduce inflammatory mediators, promote more physical ac-
tivity and decrease deconditioning, and increase exercise 
capacity, perhaps by preventing the vasoconstricting effects 
of circulating neurohumoral agents. To date, no study has 
examined the effects of CRT on skeletal muscle gene expres-
sion, biochemistry or histology. The ongoing GENSYNC
trial will hopefully shed additional light on the mechanisms 
by which CRT affects the peripheral musculature by analyz-
ing skeletal muscle biopsies prior to and six months after 
placement of a biventricular pacer.  
CONCLUSION 
  Chronic heart failure imposes an incredible economic 
burden on society and is associated with significant morbid-
ity and mortality. Although both the initial insult and etiol-
ogy of chronic heart failure are germane to hemodynamics, 
measurements of central indices fail to fully explain the as-
sociated exercise intolerance as acutely normalizing these 
hemodynamic measures does not result in improved func-
tional capacity. Instead, fatigue and exercise intolerance have 
been associated with immunologic, enzymatic and histologic 
changes in skeletal musculature. Therefore, the apparent 
“hemodynamic paradox” appears to be explained by periph-
eral maladaptations in skeletal musculature that limit oxygen 
consumption and the conversion of changes in cardiac output 
to changes in exercise tolerance. These associations are 
strongly influenced by gender and potentially reversed by a 
variety of non-pharmacologic treatments for CHF including 
exercise training and CRT. Additional research is needed to 
elucidate the molecular mechanisms of skeletal muscle dys-
function, to clarify how the phenotype is modified by gender, 
and to identify new therapeutic modalities.  
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